Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction

F W Kari1, S E Dunn, J E French

  • 1Laboratory of Environmental Carcinogenesis and Mutagenesis, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA.

Insights

Dietary restriction inhibits cancer by modulating the insulin-like growth factor-1 (IGF-1) pathway. Lowering IGF-1 levels through diet restricts tumor growth and metastasis, offering potential cancer prevention strategies.

Area of Science:

  • Endocrinology
  • Cancer Biology
  • Nutritional Science

Background:

  • Dietary restriction (DR) exhibits broad anti-carcinogenic effects across species and tumor types.
  • The insulin-like growth factor-1 (IGF-1) system acts as a key endocrine, autocrine, and paracrine signaling pathway.
  • DR's anti-cancer mechanisms are increasingly linked to its influence on the IGF-1 pathway.

Purpose of the Study:

  • To investigate the role of the IGF-1 pathway in mediating the anti-carcinogenic effects of dietary restriction.
  • To evaluate how manipulating IGF-1 levels impacts tumor growth, progression, and metastasis.
  • To explore the clinical relevance of IGF-1 in human carcinogenesis and anticarcinogenesis.

Main Methods:

  • Literature review on DR and carcinogenesis, focusing on the IGF-1 system.
  • Analysis of IGF-1 pathway response to nutritional interventions, including DR.
  • In vivo studies using animal models (mononuclear cell leukemia, bladder cancer, breast cancer) to assess tumor behavior following IGF-1 manipulation.
  • Functional disruption of the IGF-1 receptor (IGF-1R) in breast cancer metastasis models.

Main Results:

  • DR effectively inhibits carcinogenesis across various models.
  • The IGF-1 pathway is responsive to nutritional status and plays a critical role in cancer.
  • Upregulation of IGF-1 promotes tumor proliferation and metastasis, while DR-induced downregulation exhibits antitumorigenic activity.
  • Disruption of IGF-1R significantly suppresses breast cancer cell adhesion, invasion, and metastasis.

Conclusions:

  • The IGF-1 pathway is a central mediator of DR's anti-carcinogenic effects.
  • Modulating IGF-1 levels offers a promising strategy for cancer prevention and treatment.
  • IGF-1's role in regulating body size and composition suggests a link to human cancer risk and prognosis.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...